Free public records show Agios Pharmaceuticals, Inc. in 4 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Agios Pharmaceuticals, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
16 active studies led by Agios Pharmaceuticals, Inc., of 52 in all
Source: ClinicalTrials.gov, Studies with Agios Pharmaceuticals, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
1 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1439222.
Studies Agios Pharmaceuticals, Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Agios Pharmaceuticals, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Agios Pharmaceuticals, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Agios Pharmaceuticals, Inc. is in.
Stories on the topics Agios Pharmaceuticals, Inc. works in.
1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence…
Read
2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a…
Read
170 of 194 WHO member states report use of traditional medicine. Herbal products are popular, but quality and…
ReadSearch all reports for Agios Pharmaceuticals, Inc. All companies